Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril valsartan in hypertension with elevated natriuretic peptides
ChiCTR2100048161Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sacubitril + valsartan in hypertension (HTN) and None (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Change in NT-proBNP level. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2100048161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048161.